|
|
 |
|
Viewing report
|
|
|
|
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Decision Resources, Inc., Feb 2009, Pages: 368
Around the world, the market success of branded drugs is infl uenced by changes in healthcare systems and the growing role of payers – and at this point in time, economic concerns are prompting waves of change, and payers are increasingly balking at healthcare costs and seeking ways to contain expenditures. While the major-market healthcare authorities have cost-consciousness in common, they are deploying various reforms and policies in different ways in pursuit of that goal. Understanding international trends and market-specifi c measures will position biopharma players to operate optimally in a host of distinct national environments.
Questions Answered in This Report
- In November 2008, the U.S. presidential elections yielded a new Democratic administration and Congress. What are the healthcare goals of the new administration? What progress has been made thus far? What are the implications for the biopharmaceutical industry?
- Also in November 2008, the U.K. Department of Health announced a series of key reforms. How will drug prices be affected? What are the newest NICE-related adjustments?
- Use of lower priced generics is a well-established cost-containment measure. How great is the presence of generics in each major market? How are countries prompting increased use of generics? When and how will generic versions of biologics (biosimilars) affect the sales of branded pharmaceuticals?
- In a cost-conscious environment, drug prices are under scrutiny. What are the key pricing trends in the major markets? How are prices set and adjusted in each market? What strategies are healthcare authorities and pharma companies using in their pricing negotiations?
Scope
- Major markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Infrastructure: health system organization, funding sources, reform trends.
- Drug pricing and reimbursement: price-setting policies, price control measures, prices by major market, prices by drug type, outpatient drug pricing approaches, hospital drug approaches.
- Cost-control measures: biosimilars, dereimbursement, generics, fl exible pricing contracts, formularies, health technology assessment, importation, incentive programs, multitier formularies, parallel imports, patient copayment and coinsurance, prescribing budgets, price controls, prior authorization, quantity limits, reference pricing, step therapy, therapeutic substitution.
- International trends: health technology assessment, generics and biosimilars, specialty pharmaceuticals, flexible pricing arrangements, evidence of innovation.
Customers who bought this item also bought
Pharmaceutical Pricing and Reimbursement in China
Pricing & Reimbursement - Seven Major Markets Update
Pharmaceutical Pricing and Reimbursement in France, 2008
Pharmaceutical Pricing and Reimbursement in Italy, 2008
Pharmaceutical Pricing and Reimbursement in Spain, 2008
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pharmaceutical Pricing and Reimbursement in Japan, 2008
The Pricing and Reimbursement Environment for Neurology Drugs
Pricing and Reimbursement in the United Arab Emirates
Pharmaceutical Pricing and Reimbursement in India
Pricing and Reimbursement of Next Generation Diagnostics in the United States
Valuing Pharmaceutical Innovation: Pricing and Reimbursement for Innovative Therapies
|
|
|
|
